Hüseyin ASLAN, İsmail ŞİMŞİR, Elif KÖSE, Gülsen TOPAKTAŞ

COVID-19 maliyetleri; Türkiye’de bir il örneği

Amaç: Coronavirüs Hastalığı (COVID-19) pandemisinin tüm dünyada olduğu gibi Türkiye’de de olumsuz etkilri olmuştur. COVID 19’un etkilerinden biri, pandemi sonrası ülkelerde sağlık hizmetlerinde yapılan önemli harcama artışları olmuştur. Bu çalışmadaki amacımız; COVID 19 vakalarında ayaktan, yatarak ve yoğun bakımda tedavi sıklığını, yatarak ve yoğun bakım tedavi oranlarını etkileyen faktörleri belirlemek ve hasta özelliklerine göre sağlık bakım maliyetlerindeki değişimleri incelemektir. Yöntem: Bu araştırma, kesitsel bir kayıt incelemesidir. Bu çalışmanın evrenini, pandeminin Türkiye’de ilk görüldüğü 11 Mart 2020 tarihinden 30 Kasım 2020 tarihine kadar COVID-19 tanısı konularak tedavi gören, ayaktan ve yatarak tedavi gören hastalar oluşturmaktadır. Sakarya ilindeki tüm birinci, ikinci ve üçüncü basamak sağlık kuruluşlarından COVID-19 tanısı, komorbidite, yaş (

COVID-19 costs: an example of province in Turkey

Objective: The Coronavirus Disease (COVID-19) pandemic continues to negatively affect Turkey, as it does many other areas all over the world. One effect of COVID 19 has been the significant expenditure increases in health services in post-pandemic countries. Our aim for this study was the following: determining the frequency of outpatient, inpatient, and intensive care treatment in COVID-19 cases, the factors affecting the rates of inpatient and, intensive care treatments, and examining the changes in healthcare costs according to patient characteristics. Methods: This research is a cross-sectional record review. The universe of this study is composed of outpatients and inpatients that have been treated after being diagnosed with COVID 19 as from March 11, the date the pandemic was first seen in Turkey, to November 30, 2020. Within the scope of the study, data relating to the COVID-19 diagnosis, comorbidity, age (

PDF

___

1. Alpar, R. (2020). Spor Sağlık ve Eğitim Bilimlerinden Örneklerle Uygulamalı İstatistik ve Geçerlik Güvenirlik - SPSS de Çözümleme Adımlari ile Birlikte-. Detay Yayıncılık.
2. Bhatt AS, Moscone A, McElrath EE, Varshney AS, Claggett BL, Bhatt DL, et al. Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. Journal of the American College of Cardiology, 76(3), 280–8.
3. Brahmbhatt, M., & Dutta, A. (2008). On SARS type economic effects during infectious disease outbreaks. World Bank Policy Research Working Paper, 4466.
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395(10223), 507–13.
5. Darab MG, Keshavarz K, Sadeghi E, Shahmohamadi J, Kavosi Z. (2021). The economic burden of coronavirus disease 2019 (COVID-19): evidence from Iran. BMC Health Services Research, 21(1), 1–7.
6. Garg S, Kim L, Whitaker M, Cummings C, Holstein R, Prill M, et al. MMWR - Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. Morbidity and Mortality Weekly Report, 69(15), 458–64.
7. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARSCoV- 2 Admitted to ICUs of the Lombardy Region, Italy. JAMA, 323(16), 1574–81.
8. Jin H, Wang H, Li X, Zheng W, Ye S, Zhang S, et al. Economic burden of covid-19, china, january– march, 2020: A cost-of-illness study. Bulletin of the World Health Organization, 99(2), 112–24.
9. Lee JW, McKibbin WJ. Estimating the global economic costs of SARS. Learning from SARS: Preparing for the next Disease Outbreak: Workshop Summary, 92–109.
10. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. Aging and Disease, 11(3), 668–78.
11. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. American Journal of Physiology - Endocrinology and Metabolism, 318(5), E736–E741.
12. Nurchis MC, Pascucci D, Sapienza M, Villani L, D’ambrosio F, Castrini F, et al. Impact of the Burden of COVID-19 in Italy: Results of Disability- Adjusted Life Years (DALYs) and Productivity Loss. International Journal of Environmental Research and Public Health, 17(12), 4233.
13. Oostenbrink JB, Buijs-Van der Woude T, van Agthoven M, Koopmanschap MA, Rutten FF. Unit costs of inpatient hospital days. Pharmacoeconomics, 21(4), 263–71.
14. Robilotti EV, Esther B, Mead PA, Rolling T, Perez- Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nature Medicine, 26(8), 1218–23.
15. Sharma G, Volgman AS, Michos ED. Sex Differences in Mortality From COVID-19 Pandemic. JACC: Case Reports, 2(9), 1407–10.
16. T.C. Sağlık Bakanlığı COVID-19 Bilgilendirme Platformu. (2020).
17. Tandon A, Ivatts S, Cowley P, Roubal T, Dodd R, Pepperall J, et al. Economic Contraction from COVID-19 in the Pacific: Implications for Health Financing. Health Systems & Reform, 6(1), e1847991 (6 pages).
18. Wang X, Fang X, Cai Z, Wu X, Gao X, Min J, et al. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis. Research, 2020(Article ID 2402961), 1–17.
19. Wenham C, Smith J, Morgan R. (2020). COVID-19: the gendered impacts of the outbreak. In The Lancet (Vol. 395, Issue 10227, pp. 846–848). Lancet Publishing Group.